The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Autism Acceptance Month: Autism in Clinical Practice—Communication Strategies and Considerations for Better Care
- Sleep Awareness Week: Why Sleep Health Should Be Part of Every Wellness Visit
- Heart Health Month in Practice: What Clinicians Should Watch for in February
- National Blood Donor Month: How Clinicians Can Encourage Lifesaving Donations
- Holiday Health Hazards: Common ER Visits and How to Prevent Them